Eli Lilly CEO Dave Ricks reported that 700,000 new seniors enrolled in GLP-1 obesity treatments through Medicare coverage since July, with 70% using Lilly drugs. Lilly's Zepbound injection and newly launched Foundayo pill are capturing the majority of new patients, with Ricks attributing success to physician preference for treating patients with higher weight and complications.
Eli Lilly is investing $6.5 billion to build a major pharmaceutical manufacturing campus in Houston, expected to produce pill-form GLP-1 weight-loss drugs and other small-molecule medicines. The 236-acre facility will create approximately 600 permanent jobs and 4,000 construction positions, while the company is also funding $15 million in workforce development at San Jacinto College. Construction begins now with completion targeted for November 2027.